乳腺癌内分泌治疗耐药机制的研究进展

乳腺癌是中国女性常见的恶性肿瘤之一，严重威胁着人们的健康和生命。70%~80%乳腺癌为激素受体阳性，目前针对这一类型乳腺癌的主要治疗手段为内分泌治疗。近几十年来内分泌治疗领域的新药不断问世并逐渐应用于临床，虽然对提高患者的疗效和延长生存时间方面带来希望，但内分泌治疗的耐药现状也受到人们重视。本文将对乳腺癌内分泌治疗的耐药机制和最新的研究结果进行综述，以期为乳腺癌内分泌治疗耐药的早期监测和干预提供新的思路。 

Research advances in mechanisms of endocrine therapy resistance for breast cancer

In China breast cancer is one of the common cancers for female, which seriously threatens people's health and life. Seventy to eighty percent of breast cancers are estrogen receptor (ER)-positive tumors. Endocrine therapy is the main strategy for ER-positive breast cancer. Novel endocrine drugs, which have brought hopes to improve the therapeutic effect and prolong the overall survival of patients, have been created and used for patients with ER-positive breast cancer in the recent decades. However, the resistance to endocrine therapy has gradually emerged to be a severe problem. In order to provide new ideas targeting endocrine resistance for early prediction and treatment of ER-positive breast cancer, we combined the current theory and mechanism of endocrine resistance, as well as the latest published research results in this review.